How do the results of KEYNOTE-B15/EV-304 influence your preferred treatment for cisplatin eligible MIBC?
Which patients will you still use perioperative durva/cis/gem? Are there toxicities you've encountered that don't overlap where you could be a cis/gem candidate but not an EV candidate?
Community PollStarted
What will be your preferred systemic therapy for patients with localized MIBC who are cisplatin eligible?
88 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Northwestern University
Answered on
The management of urothelial cancer has undergone major changes in the last decade.
We have seen a number of new drugs approved for relapsed BCG-refractory superficial bladder cancer. Additionally, we have seen a number of new approaches for the management of muscle-invasive bladder cancer (MIBC) or ...
Join for free or sign in to see the full answer